source
- GSK to acquire cancer-focused biotech Nuvalent for $10.6 billionGSK announced it will acquire Nuvalent, a biotech that develops targeted cancer therapies, in a transaction valued at $10.6 billion. The purchase price translates to $124 per Nuvalent share, a 26%…
- U.S. drug shortages drop 23% but average duration climbs to over five years, analysis showsThe latest U.S. Pharmacopeia analysis reports that the total number of prescription drug shortages fell by 23% last year, marking the second year of decline and the lowest level since 2017. Despit…